Related Experiment Video
Updated: Jul 3, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
[Systemic lupus erythematosus: future therapeutic avenues]
Z Amoura1, J Haroche, J-C Piette
1Service de médecine interne 2, centre national de référence Lupus et syndrome des anticorps antiphospholipides, université Pierre-et-Marie-Curie, Paris-6, CHU Pitié-Salpétrière, 75013 Paris cedex 13, France. zahir.amoura@psl.aphp.fr
During the last decade, new biotherapies have been developed for the treatment of systemic autoimmune diseases, especially for systemic lupus erythematosus (SLE). These new approaches are based on a better understanding of the auto-immune response. Targets of these new treatments are all the steps of the immune response. These new therapies are: (1) "B lymphocyte (BL)" inhibitors such as anti-CD20 monoclonal antibody, anti-CD22 monoclonal antibody, BlyS antagonists, tolerogens of pathogenic-antibody secreting LB (LJP 394) and edratide; (2) "Inhibitors of the costimulation" between antigen-presenting cells and T lymphocyte (TL) like monoclonal anti-CD40 ligand antibody or CTLA-4-Ig (abatacept); (3) "Cytokine antagonists" inhibiting key cytokines of SLE: interleukin-10, interferon-alpha, interleukin-6 and TNF. These new therapies are currently under development in SLE.
During the last decade, new biotherapies have been developed for the treatment of systemic autoimmune diseases, especially for systemic lupus erythematosus (SLE). These new approaches are based on a better understanding of the auto-immune response. Targets of these new treatments are all the steps of the immune response. These new therapies are: (1) "B lymphocyte (BL)" inhibitors such as anti-CD20 monoclonal antibody, anti-CD22 monoclonal antibody, BlyS antagonists, tolerogens of pathogenic-antibody secreting LB (LJP 394) and edratide; (2) "Inhibitors of the costimulation" between antigen-presenting cells and T lymphocyte (TL) like monoclonal anti-CD40 ligand antibody or CTLA-4-Ig (abatacept); (3) "Cytokine antagonists" inhibiting key cytokines of SLE: interleukin-10, interferon-alpha, interleukin-6 and TNF. These new therapies are currently under development in SLE.
Related Concept Videos
iPS Cell Differentiation
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Nephrotic Syndrome II : Assessment and Medical Management
Targeted Cancer Therapies
There are several types of targeted therapies against specific...